PancreaCult™ Pancreatic Organoid Growth Medium (Mouse)

总览

PancreaCult™胰腺类器官培养基（小鼠）是一款无血清、成分明确的细胞培养基，用于建立和维持小鼠胰腺外分泌类器官。这些类器官或“迷你胰腺”为研究胰腺细胞生物学、疾病和癌症提供了体外器官型培养系统。在PancreaCult™中生长的类器官具有表达胰腺干细胞（LGR5），祖细胞（PDX1, SOX9）和导管细胞（CAR2, MUC1, KRT19）标志物。胰腺类器官可每3 - 6天传代一次，以便长期维持，也可冷冻保存。

PancreaCult™ 支持小鼠胰腺类器官培养的培养，无论是嵌入Corning®Matrigel®dome还是在稀释的Matrigel®中进行悬浮培养。类器官培养提供了一个便捷的体外系统，用于表征胰腺上皮，具有生理相关性，减少了动物使用的需求。

如果您打算将本产品用于商业目的，请通过www.huborganoids.nl与HUB联系，以获取商业用途许可或HUB许可相关的说明。

PancreaCult™ 支持小鼠胰腺类器官培养的培养，无论是嵌入Corning®Matrigel®dome还是在稀释的Matrigel®中进行悬浮培养。类器官培养提供了一个便捷的体外系统，用于表征胰腺上皮，具有生理相关性，减少了动物使用的需求。

如果您打算将本产品用于商业目的，请通过www.huborganoids.nl与HUB联系，以获取商业用途许可或HUB许可相关的说明。

PancreaCult™ 支持小鼠胰腺类器官培养的培养，无论是嵌入Corning®Matrigel®dome还是在稀释的Matrigel®中进行悬浮培养。类器官培养提供了一个便捷的体外系统，用于表征胰腺上皮，具有生理相关性，减少了动物使用的需求。

如果您打算将本产品用于商业目的，请通过www.huborganoids.nl与HUB联系，以获取商业用途许可或HUB许可相关的说明。

PancreaCult™ 支持小鼠胰腺类器官培养的培养，无论是嵌入Corning®Matrigel®dome还是在稀释的Matrigel®中进行悬浮培养。类器官培养提供了一个便捷的体外系统，用于表征胰腺上皮，具有生理相关性，减少了动物使用的需求。

如果您打算将本产品用于商业目的，请通过www.huborganoids.nl与HUB联系，以获取商业用途许可或HUB许可相关的说明。

亚型
专用培养基

细胞类型
胰腺细胞

应用
细胞培养，扩增，培养，类器官培养

品牌
PancreaCult

研究领域
癌症，疾病建模，药物发现和毒理检测，上皮细胞研究，类器官，干细胞生物学，移植研究

制剂类别
无血清

查看更多显示更少

实验数据

Figure 1. Organoids Grown in PancreaCult™ Organoid Growth Medium (Mouse)

Pancreatic exocrine organoids are observed within one week when cultured in (A) Corning® Matrigel® domes or (B) a dilute Matrigel® suspension. Organoids were imaged during passage 2, on day 4.

Figure 2. Mouse Pancreatic Organoids can be Initiated from a Variety of Starting Materials

PancreaCult™ Organoid Growth Medium (Mouse) enables the initiation of pancreatic exocrine organoids from (A) duct fragments, (B) single cells and (C) cryopreserved organoid fragments. All organoids were grown in Matrigel® domes. Organoids were imaged on day 4 or day 5 of primary culture (duct fragments and single cells, respectively) or day 3 of the first passage post-thaw (cryopreserved organoids).

Figure 3. Pancreatic Organoids can be Grown in Matrigel® Domes or as a Dilute Matrigel® Suspension

Organoids cultured using PancreaCult™ Organoid Growth Medium (Mouse) from freshly isolated pancreatic tissue fragments and plated in (A) Matrigel® domes or (B) as a dilute Matrigel® suspension. Organoids grown in either culture condition are typically ready for passage within 3 - 6 days.

Figure 4. Pancreatic Exocrine Organoids Display Markers of Pancreatic Progenitor and Ductal Cells

Pancreatic exocrine organoids grown in PancreaCult™ and stained for nuclei (DAPI, blue), ductal marker KRT19 (green) and pancreatic progenitor marker PDX1 (red). Organoids were imaged during passage 12 on day 5. Note: The folded appearance of epithelium is a function of cryosectioning and not representative of the shape of proliferating organoids.

Figure 5. Pancreatic Exocrine Organoids Retain Pancreatic Marker Expression During Passaging

Pancreatic organoids express stem cell markers and those typical of the pancreatic exocrine system, including (A) Axin2, (B) Krt19, (C) Muc1 and (D) Pdx1. Relative quantification (RQ) of each marker is reported relative to the 18S and TBP housekeeping genes and normalized to C57/Bl6 pancreatic tissue. Marker expression was assayed during early passages (passage 1-5) and late passages (passage 6-10).

Figure 6. Expansion of Organoids Grown in PancreaCult™ Organoid Growth Medium (Mouse)

Organoids cultured with PancreaCult™ Organoid Growth Medium (Mouse) show efficient growth over multiple passages. Cultures were split with an average split ratio of 1:16 at each passage.

Figure 7. Pancreatic Exocrine Organoids Provide a Model for Pancreatic Carcinomas

PancreaCult™ Organoid Growth Medium (Mouse) supports the growth of organoids from pancreatic carcinomas. Pancreatic ducts were isolated from KPC mice (Kras+/LSL-G12D; Trp53+/LSL-R172H; Pdx1-Cre) and cultured in PancreaCult™ Organoid Growth Medium (Mouse). Organoids were imaged on (A) day 4 of primary culture and (B) day three after the first passage. An activated KRAS genotype was retained in organoids during culture. Data used with permission from Dr. David Tuveson.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Information Sheet

Product Name

PancreaCult™ Organoid Growth Medium (Mouse)

Catalog #

06040

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

PancreaCult™ Organoid Growth Medium (Mouse)

Catalog #

06040

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

PancreaCult™ Organoid Growth Medium (Mouse)

Catalog #

06040

Lot #

All

Language

English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area

Workflow Stages

Workflow Stages for Organoids

View All

相关材料与文献

The CellRaft AIR? system: A novel system enabling organoid imaging, identification, and isolation A. Stern et al. SLAS Discovery 2022 4

Abstract

Three-dimensional (3D) culture systems have been developed that can re-capitulate organ level responses, simulate compound diffusion through complex structures, and assess cellular heterogeneity of tissues, making them attractive models for advanced in vitro research and discovery. Organoids are a unique subtype of 3D cell culture that are grown from stem cells, are self-organizing, and closely replicate in vivo pathophysiology. Organoids have been used to understand tissue development, model diseases, test drug sensitivity and toxicity, and advance regenerative medicine. However, traditional organoid culture methods are inadequate because they are low throughput and ill-suited for single organoid imaging, phenotypic assessment, and isolation from heterogenous organoid populations. To address these bottlenecks, we have adapted our tissue culture consumable and instrumentation to enable automated imaging, identification, and isolation of individual organoids. Organoids grown on the 3D CytoSort? Array can be reliably tracked, imaged, and phenotypically analyzed using brightfield and fluorescent microscopy as they grow over time, then released and transferred fully intact for use in downstream applications. Using mouse hepatic and pancreatic organoids, we have demonstrated the use of this technology for single-organoid imaging, clonal organoid generation, parent organoid subcloning, and single-organoid RNA extraction for downstream gene expression or transcriptomic analysis. The results validate the ability of the CellRaft AIR? System to facilitate efficient, user-friendly, and automated workflows broadly applicable to organoid research by overcoming several pain points: 1) single organoid time-course imaging and phenotypic assessment, 2) establishment of single cell-derived organoids, and 3) isolation and retrieval of single organoids for downstream applications.

View publication

A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma. N. K. Lytle et al. Cell 2019

Abstract

Drug resistance and relapse remain key challenges in pancreatic cancer. Here, we have used RNA sequencing (RNA-seq), chromatin immunoprecipitation (ChIP)-seq, and genome-wide CRISPR analysis to map the molecular dependencies of pancreatic cancer stem cells, highly therapy-resistant cells that preferentially drive tumorigenesis and progression. This integrated genomic approach revealed an unexpected utilization of immuno-regulatory signals by pancreatic cancer epithelial cells. In particular, the nuclear hormone receptor retinoic-acid-receptor-related orphan receptor gamma (ROR$\gamma$), known to drive inflammation and T cell differentiation, was upregulated during pancreatic cancer progression, and its genetic or pharmacologic inhibition led to a striking defect in pancreatic cancer growth and a marked improvement in survival. Further, a large-scale retrospective analysis in patients revealed that ROR$\gamma$ expression may predict pancreatic cancer aggressiveness, as it positively correlated with advanced disease and metastasis. Collectively, these data identify an orthogonal co-option of immuno-regulatory signals by pancreatic cancer stem cells, suggesting that autoimmune drugs should be evaluated as novel treatment strategies for pancreatic cancer patients.

View publication

View All Publications